Eli Lilly (LLY)

There are other factors to consider before investing in this -- or any other -- healthcare company.

It's acquiring an asset with a very promising lead drug candidate.

MeiraGTx reacquires bota-vec from Johnson & Johnson, outlining regulatory plans, funding outlook, and updated xerostomia data.

Eli Lilly Foundayo shows cardiovascular safety and stronger A1C, weight reduction, while the FDA flags liver risk, seeks additional data.

Lilly's revenue has soared thanks to its obesity drugs.

And can Novo Nordisk catch up to its rival in the weight loss market?

During the last market crash, these stocks all generated positive returns -- one as high as 80%.

As of April 15, 2026, the biotechnology sector is witnessing a paradigm shift in precision oncology, spearheaded by Revolution Medicines, Inc. (Nasdaq: RVMD). Once considered a high-risk clinical-stage venture, RVMD has transformed into a late-stage powerhouse following a series of high-stakes clinical successes. The company is currently in the spotlight after a "watershed moment" on [...]

AbbVie is making progress in this market, but it is still far behind the leader.

What Happened? Shares of cloud computing and online retail behemoth Amazon (NASDAQ:AMZN) jumped 3.6% in the afternoon session after the company announced it ...

As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc. (Nasdaq: RVMD) released topline Phase 3 results from its RASolute 302 trial, effectively setting a new standard of care in the treatment of pancreatic cancer. For [...]

In April, regulators approved Foundayo, Eli Lilly's GLP-1 pill for weight loss.

As of April 13, 2026, Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX) stands as a pivotal player in the rapidly evolving field of radiopharmaceuticals—a sector that has transformed from a niche oncology sub-specialty into a multi-billion-dollar cornerstone of precision medicine. Headquartered in Melbourne, Australia, with a significant and growing footprint in the United States and [...]

As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an industry often characterized by volatile "one-hit wonders" and aggressive M&A cycles, Regeneron has carved out a unique identity as a founder-led, R&D-centric powerhouse. Currently, [...]

Eli Lilly releases positive Phase 3 data for Jaypirca and Retevmo, with trial results supporting potential label expansion.

Eli Lilly (LLY) exemplifies the GARP strategy with strong growth, reasonable valuation relative to peers, and robust profitability for sustainable returns.

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

The use of weight-loss drugs is growing like crazy and changing the entire consumer economy along with it.

And it's not too late to get in on the action.

The Vanguard S&P 500 ETF is a no-brainer for investors seeking more diversification in their portfolio.

What Happened? Shares of cloud computing and online retail behemoth Amazon (NASDAQ:AMZN) jumped 4.5% in the afternoon session after CEO Andy Jassy's annual s...

In a move that has sent shockwaves through the global consumer staples market, Unilever (NYSE:UL) and McCormick & Company (NYSE:MKC) have officially entered into a definitive agreement to merge Unilever’s expansive global food business with the Maryland-based spice giant. The $65 billion transaction, announced on March 31, 2026,

Eli Lilly launches Foundayo weight-loss pill after FDA approval, priced from $149/month, as competition with Novo Nordisk intensifies.

Eli Lilly is approaching its first-quarter earnings release this month, and Wall Street is forecasting a triple-digit percentage rise in earnings.